Drug Pipeline

KN026 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
1
Recruiting
2
Phase 3
2
Top Sponsors
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-05-19 NCT07597629 A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer Phase 2 Not Yet Recruiting
Active Studies by Phase
Phase 3
1
Phase 2/3
1
Phase 2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07441460 A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable… Resectable HER2-positive Breast Cancer Recruiting
Phase 2/3
NCT07332533 A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer HER2-positive Gastric Cancer Not Yet Recruiting
Phase 2
NCT07597629 A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer Advanced Breast Cancer Not Yet Recruiting
Sponsors Running KN026 Trials
Shanghai JMT-Bio Inc. (2) CSPC Megalith Biopharmaceutical Co.,Ltd. (1)
Disease Areas
Breast Cancer (2) Gastric Cancer (1) HER2-Positive Breast Cancer (1)
Get alerts when KN026 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free